S-OA-D
Oral Abstracts - Session D - Allogeneic Transplants
BMT Tandem "Scientific" Meeting
Texas B (Gaylord Texan)
Chairs:
Charles F. LeMaistre, MD
and
J. Alejandro Madrigal, MD, PhD
Disclosures:
C. F. LeMaistre,
Nothing To Disclose
J. A. Madrigal,
Nothing To Disclose
Value of a Consensus Panel to Adjudicate Cause-Specific Mortality after Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (URD-HCT) for Use As the Primary Endpoint in a Genome-Wide Association Study (GWAS)
Theresa Hahn, PhD, Roswell Park Cancer Institute;
Lara Sucheston-Campbell, PhD, Roswell Park Cancer Institute;
Leah Preus, MS, Roswell Park Cancer Institute;
Kenan Onel, MD, PhD, University of Chicago;
Xiaochun Zhu, MS, Medical College of Wisconsin;
Song Liu, PhD, Roswell Park Cancer Institute;
Li Yan, PhD, Roswell Park Cancer Institute;
David Tritchler, DSc, SUNY University at Buffalo;
Marcelo C. Pasquini, MD, MS, CIBMTR/Medical College of Wisconsin;
Philip L. McCarthy, MD, Roswell Park Cancer Institute
Prospective PCR Monitoring Reveals Adenovirus (ADV) Viremia Is Associated with a Significant Risk of Adv Disease in T-Cell Depleted and Cord Blood Allograft Recipients
Yao-Ting Huang, PhD, MPH, Memorial Sloan-Kettering Cancer Center;
Yeon Joo Lee, MD, MPH, Memorial Sloan-Kettering Cancer Center;
Yovanna Kolitsopoulos, BS, Memorial Sloan-Kettering Cancer Center;
Julia Foldi, PhD, Memorial Sloan-Kettering Cancer Center;
Susan K. Seo, MD, Weill Medical College, Cornell University;
Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center;
Juliet N. Barker, MBBS, FRACP, Memorial Sloan-Kettering Cancer Center;
Ann A. Jakubowski, MD, PhD, Memorial Sloan-Kettering Cancer Center;
Genovefa Papanicolaou, MD, Memorial Sloan-Kettering Cancer Center
Hematopoietic Cell Transplantation in Patients with Systolic Heart Failure: Can It be Done?
Peter J. Hurley, MD, University of Minnesota;
Anne Blaes, MD, MS, University of Minnesota;
Qing Cao, University of Minnesota;
Suma Konety, M.D., M.S., University of Minnesota;
Daniel J. Weisdorf, MD, University of Minnesota
Extended Follow-up of Myeloablative, HLA-Matched Allogeneic BMT with High-Dose, Post-Transplantation Cyclophosphamide (PTCy) As Sole GVHD Prophylaxis: Favorable Outcomes Despite Low Incidence of Chronic GVHD
Christopher G. Kanakry, MD, The Johns Hopkins University School of Medicine;
Hua-Ling Tsai, MS, The Johns Hopkins University School of Medicine;
Javier Bolaņos-Meade, MD, The Johns Hopkins University School of Medicine;
B Douglas Smith, MD, The Johns Hopkins University School of Medicine;
Ivana Gojo, MD, The Johns Hopkins University School of Medicine;
Yvette L. Kasamon, MD, The Johns Hopkins University School of Medicine;
Jennifer A. Kanakry, MD, The Johns Hopkins University School of Medicine;
Marianna Zahurak, MS, The Johns Hopkins University School of Medicine;
Ephraim Fuchs, MD, The Johns Hopkins University School of Medicine;
Richard J. Jones, MD, The Johns Hopkins University School of Medicine;
Leo Luznik, MD, The Johns Hopkins University School of Medicine
